Sirolimus Drug-coated Balloon Versus Stent Graft (SUSTAIN)
Arteriovenous Shunt Thrombosis, Blood Vessel Prosthesis
About this trial
This is an interventional treatment trial for Arteriovenous Shunt Thrombosis focused on measuring Arteriovenous graft, Thrombosis, Sirolimus, Drug-coated balloon, stent graft
Eligibility Criteria
Inclusion Criteria: Thrombosed AVG in the upper arm Successful thrombolysis of the thrombosed AVG, defined as the re-established of flow on Digital Subtraction Angiography (DSA) and restoration of thrill in the AVG on clinical examination (to be determined during procedure) Exclusion Criteria: Patient unable to provide informed consent Previous bare metal stent or stent-graft placement within the dialysis access Previous treatment with DCB within 3 months Presence of central vein stenosis which cannot be adequately treated (residual recoil of more than 30%) Failure to re-establish blood flow Failure to adequately treat the GV junction (defined as residual stenosis of more than 30%) Sepsis or active infection Recent intracranial bleed or gastrointestinal bleed within the past 12 months Allergy to iodinated contrast media, anti-platelet drugs, heparin or sirolimus Pregnancy Life expectancy < 12 months based on physician's estimate (eg. active malignancy)
Sites / Locations
- Singapore General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Sirolimus drug-coated balloon
Stent graft
The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the graft vein junction by inflating the balloon for 2 minutes at rated burst pressure (typically 12 to 14ATM).
Stent graft is the current standard of care for treatment of arteriovenous graft malfunction. A stent graft will be deployed at the graft vein junction.